Zealand Pharma A/S (ZEAL.CO)
ValueMarkers Composite Index
DCF data not available
Zealand Pharma A/S (ZEAL.CO) — VMCI valuation read
ZEAL.CO prints VMCI 72/100 inside the Healthcare sector, where the median sits at 50. The 22-point above-median delta is the cleanest single-number summary of Zealand Pharma A/S's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On ZEAL.CO, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** ZEAL.CO trades at 22.0x earnings, 22% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -1.9x leaves covenant headroom; that is the risk line for Zealand Pharma A/S on the trailing financials.
ZEAL.CO rose 3.1% over the trailing 7 days, with a +2.1% read on a 30-day basis.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.